Lineage Cell Therapeutics (LCTX) Other financing activities (2010 - 2026)

Lineage Cell Therapeutics' Other financing activities history runs 15 years deep, the most recent figure standing at $227000.0 for Q1 2026.

• On a quarterly basis, Other financing activities changed N/A year-over-year to $227000.0 in Q1 2026; TTM through Mar 2026 was $1.5 million, a 1422.68% increase from a year earlier, with the FY2025 full-year figure at $1.2 million, up 445.85% from the prior year.
• Other financing activities eased to $227000.0 in Q1 2026 per LCTX's latest filing, from $763000.0 in the prior quarter.
• Across five years, Other financing activities topped out at $892000.0 in Q3 2022 and bottomed at -$343000.0 in Q4 2022.
• The 5-year median for Other financing activities is $87000.0 (2024), against an average of $187846.2.
• Across the five-year window, Other financing activities sank 135.32% in 2022 and soared 4770.0% in 2025, its largest moves.
• Year by year, Other financing activities stood at -$343000.0 in 2022, then jumped by 102.33% to $8000.0 in 2023, then grew by 25.0% to $10000.0 in 2024, then surged by 7530.0% to $763000.0 in 2025, then tumbled by 70.25% to $227000.0 in 2026.
• Per Business Quant, the three latest LCTX Other financing activities figures stand at $227000.0 (Q1 2026), $763000.0 (Q4 2025), and $487000.0 (Q3 2025).